Trial reportOphthalmology2015
Association of Baseline Characteristics and Early Vision Response with 2-Year Vision Outcomes in the Comparison of AMD Treatments Trials (CATT).
Trial report in Ophthalmology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00593450 (Comparison of Age-related Macular Degeneration Treatments Trials), which is not on this map. Cited by 56 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial (CATT)
Who cites it
56 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.The Cochrane database of systematic reviews · 2020Pooled it
- Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.The Cochrane database of systematic reviews · 2019Pooled it
- Predicting Visual Acuity Responses to Anti-VEGF Treatment in the Comparison of Age-related Macular Degeneration Treatments Trials Using Machine Learning.Ophthalmology. Retina · 2024Trial
- Prediction for 2-Year Vision Outcomes Using Early Morphologic and Functional Responses in the Comparison of Age-related Macular Degeneration Treatments Trials.Ophthalmology. Retina · 2023Trial
- Early Response to Anti-Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes With Diabetic Macular Edema in Protocol T.American journal of ophthalmology · 2018Trial
- Changes in Blood Pressure and Urine Albumin-Creatinine Ratio in a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.Investigative ophthalmology & visual science · 2018Trial
- Aflibercept 8 mg in neovascular age-related macular degeneration and diabetic macular oedema: Translating clinical trials into clinical practice.Eye (London, England) · 2026Review
- Long-term outcomes of nationwide coordinated neovascular AMD treatment: A study based on Polish national registry.Acta ophthalmologica · 2026Article
- Real-World Experience with Brolucizumab in Treatment-Naïve nAMD with Low Baseline Visual Acuity: Short-Term Outcomes from a Prospective Single-Institution Study.Life (Basel, Switzerland) · 2026Article
- OCT-based morphological prognostic factors for structural improvement after anti-VEGF therapy in wet age-related macular degeneration.BMC ophthalmology · 2026Article
- Interpreting OCT Predictors of Visual Response During Aflibercept Treat-and-Extend Therapy [Letter].Drug design, development and therapy · 2026Article
- Visual outcome following initiation of first injection versus after three monthly doses of aflibercept 2 mg for treatment naïve age-related macular degeneration to inform clinical trial designs: PRECISE Report No. 6.Eye (London, England) · 2025Article
- Simultaneous GA and CNV/MNV: incidence, characteristics, and treatments.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Review
- Recurrence of neovascular age-related macular degeneration after discontinuation of modified treat and extend treatment.Scientific reports · 2025Article
- Systemic oxidative stress levels and their associations with the risk of neovascular age-related macular degeneration and treatment response.International journal of retina and vitreous · 2025Article
- A 5-Year Analysis of Optical Coherence Tomography Biomarkers in The Visual Outcomes of an As-Needed Treatment Algorithm for Neovascular Age-Related Macular Degeneration.Beyoglu eye journal · 2025Article
- Pneumatic displacement of submacular haemorrhage secondary to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.Eye (London, England) · 2024Article
- Baseline optical coherence tomography angiography biomarkers predict visual outcomes in treatment-naïve neovascular age-related macular degeneration patients.Scientific reports · 2024Article
- Associations of presenting visual acuity with morphological changes on OCT in neovascular age-related macular degeneration: PRECISE Study Report 2.Eye (London, England) · 2024Article
- Predicting long-term functional anti-VEGF treatment outcomes in neovascular AMD in a real-world setting.PloS one · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeTo evaluate the association of baseline characteristics and early visual acuity (VA) response with visual outcomes at years 1 or 2 in the Comparison of Age-Related Macular Degeneration (AMD) Treatments Trials (CATT).
designSecondary analysis of CATT.
participantsThe 1185 CATT participants with baseline VA of 20/25 to 20/320.
methodsParticipants were assigned to ranibizumab or bevacizumab and to 1 of 3 dosing regimens. Associations of baseline characteristics and early VA response (week 4 or 12) with VA response at years 1 or 2 were assessed by R(2) from linear regression analyses. Patients who had a poor initial response (VA 20/40 or worse with persistent fluid and without ≥1-line VA gain) were defined as candidates for changing treatment.
main outcome measuresVisual acuity change from baseline.
resultsStatistically significant (P < 0.05) baseline predictors for less VA gain at year 2 were older age, VA of 20/40 or better, larger choroidal neovascularization area, presence of geographic atrophy, total foveal thickness ≤325 μm or ≥425 μm, and elevation of retinal pigment epithelium. Among 176 eyes gaining ≥3 lines at week 12, 78% had a ≥3-line gain at year 2, whereas among 113 eyes losing ≥1 line at week 12, 27% improved to a ≥1-line gain at year 2. Visual acuity response at week 12 was more predictive of VA response at year 2 (R(2) = 0.30) than VA response at week 4 (R(2) = 0.17) and baseline predictors (R(2) = 0.13; P < 0.0001). Among 126 candidates for changing treatment drug at week 12, mean VA improved by 2.8 letters (P = 0.050), mean total retinal thickness decreased 53 μm (P < 0.0001), and fluid resolved in 33% (P < 0.0001) between week 12 and year 1 with continued use of the same drug and regimen. Similar improvements were observed among 83 candidates for changing drugs at week 24.
conclusionsVisual acuity response at week 12 is more predictive of 2-year vision outcomes than either several baseline characteristics or week 4 response. Eyes with poor initial response may benefit from continued treatment without switching to another drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.